# Summary of Safety & Effectiveness UniCel DxC SYNCHRON Systems Glucose (GLUH) reagent

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.

# 1.0 Submitted By:

Yvette Lloyd   
Consultant   
Beckman Coulter, Inc.   
250 S. Kraemer Blvd   
Mail Stop: E1.SE.01   
Brea, CA 92821   
Phone: (714) 307-3469   
FAX: (714) 961-4234   
email: yrlloyd@beckman.com

2.0 Date Submitted:

April 4, 2014

3.0 Device Name(s):

3.1 Proprietary Names UniCel DxC SYNCHRON Systems Glucose reagent (GLUH)

# 3.2 Classification Name

Glucose test system (21 CFR 862.1345, Product Code CFR)

4.0 Predicate Devices:

<table><tr><td rowspan=1 colspan=1>CANDIDATE</td><td rowspan=1 colspan=1>PREDICATE (K#)</td><td rowspan=1 colspan=1>Classification— Regulation</td><td rowspan=1 colspan=1>ClassificationPanel</td><td rowspan=1 colspan=1>ProductCode</td></tr><tr><td rowspan=1 colspan=1>UniCel DxCSYNCHRONSystemsGLUH</td><td rowspan=1 colspan=1>Beckman Coulter GLUassay (K883181)</td><td rowspan=1 colspan=1>Class II862.1345</td><td rowspan=1 colspan=1>75 (ClinicalChemistry)</td><td rowspan=1 colspan=1>CFR</td></tr></table>

# NOSTI 34A

# Description:

Reagent:

GLUH reagent is used to measure the glucose concentration by a timed endpoint method. In the reaction, hexokinase (HK) catalyses the transfer of a phosphate group from adenosine triphosphate (ATP) to glucose to form adenosine diphosphate (ADP) and glucose-6- phosphate. The glucose-6-phosphate is then oxidized to 6-phosphogluconate with the concomitant reduction of $\beta$ -nicotinamide adenine dinucleotide (NAD) to reduced $\beta$ - nicotinamide adenine dinucleotide (NADH) by the catalytic action of glucose- $6$ phosphate dehydrogenase (G6PDH).

The UniCel® DxC 600/800 SYNCHRON System(s) automatically proportions the appropriate sample and reagent volumes into the cuvette. The ratio used is one part sample to 100 parts reagent. The system monitors the change in absorbance at 340 nanometers. This change in absorbance is directly proportional to the concentration of glucose in the sample and is used by the System to calculate and express glucose concentration.

The GLUH uses the following chemical reaction scheme:

Gucose eADP Glucose-6-phosphate + NAD+G6PDH6-phosphogluconate + NADH + H ca94ps

# 6.0 Intended Use:

INTENDED USE

UniCel DxC sYNCHRON Systems Glucose reagent (GLUH), when used in conjunction with UniCe $\Cap$ DxC 600/800 SYNCHRON System(s) and SYNCHRON Systems AQUA CAL 1 and 3, is intended for the quantitative determination of glucose concentration in human serum, plasma, urine or cerebrospinal fluid (CSF).

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.

# 7.0 Comparison to Predicate(s):

The following tables show the smilarities and differences between themodifid device and the predicate device identified in Section 4.0 of this summary.

List of design inputs that are same/similar between the two reagent devices   

<table><tr><td colspan="1" rowspan="1">Characteristics</td><td colspan="1" rowspan="1">UniCel DxCSYNCHRONSystems GLUHReagent</td><td colspan="1" rowspan="1">SYNCHRON Systems LX and UniCel DxC GLUreagent (K883181)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Intended for the quantitative determination ofglucose using serum, plasma, urine, or CSF as asample type.</td></tr><tr><td colspan="1" rowspan="1">Clinicalindications.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Glucose measurements are used in the diagnosisand treatment of carbohydrate metabolismdisorders including diabetes mellitus, neonatalhypoglycemia, idiopathic hypoglycemia, andpancreatic islet cell carcinoma.</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Timed endpoint method</td></tr><tr><td colspan="1" rowspan="1">Reactionprinciple</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Gkxose + AJP -HKgucose-6posphete + AOPGkuose6phashate + NUD* GEPOH  6-phosphoglcorate + NADH: + H</td></tr><tr><td colspan="1" rowspan="1">FundamentalTechnology</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Spectrophotometric detection</td></tr><tr><td colspan="1" rowspan="1">System use</td><td colspan="1" rowspan="1">Same (NOTE:GLUH is onlyapplied to the DxC600/800 systems)</td><td colspan="1" rowspan="1">For use on clinical chemistry analyzers</td></tr><tr><td colspan="1" rowspan="1">Analytic Range</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">5-700 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">SYNCHRON Systems Glucose reagent,REAGENT CONSTITUENTS:Adenosine Triphosphate, 3.8 mmol/L; NAD+, 2.7mmol/L; Hexokinase, 2.0 KIU/L; Glucose-6-phosphate dehydrogenase, 3.0 KIU/L;Also non-reactive chemicals necessary for optimalsystem performance.</td></tr><tr><td colspan="1" rowspan="1">ReferenceIntervals</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Sample type  rangeSerum/plasma 74-106 mg/dLUrine           1-15 mg/dLUrine (timed)  &lt;0.5g/24 hoursCSF            40-70 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Sample Storageand Stability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum/plasma1. 8 hours at +20°C to +25°2. 48 hours at +2°C to +8°3. &gt; 48 hours at ≤ -15 to -20°Serum/plasma1. 1 freeze/thaw cycle (when stored at -15 to -20°C</td></tr><tr><td colspan="1" rowspan="1">Linearity</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Analytical range = 5-700mg/dL, with sample dilutionusing saline for samples exceeding the high end ofthe linear range.</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum/plasma, CSF, urine</td></tr><tr><td colspan="1" rowspan="1">Within runPrecision Claims</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">SD - 2.0 mg/dLCV -2.0%</td></tr><tr><td colspan="1" rowspan="1">Total PrecisionClaims</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">SD - 3.0 mg/dLCV - 3.0%</td></tr><tr><td colspan="1" rowspan="1">Reagent OnBoard Stability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">30 days</td></tr><tr><td colspan="1" rowspan="1">Calibrationstability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">14 days</td></tr><tr><td colspan="1" rowspan="1">Within lotcalibration</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">90 days</td></tr></table>

List of design inputs that are different between the two reagent devices   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>UniCel DxC SYCNHRON SystemsGLUH Reagent</td><td rowspan=1 colspan=1>SYNCHRON Systems LX and UniCelDxC GLU&#x27;reagent (K883181)</td></tr><tr><td rowspan=1 colspan=1>Calibrator used</td><td rowspan=1 colspan=1>SYNCHRON SystemS AQUA CAL 1SYNCHRON Systems AQUA CAL 3(K071277)</td><td rowspan=1 colspan=1>SYNCHRON MultiCal (K110251)</td></tr><tr><td rowspan=1 colspan=1>Calibrator Stability(opened)</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>20 days</td></tr><tr><td rowspan=1 colspan=1>InterferencesBilirubinHemoglobinLipemiaAscorbic AcidUreaUric AcidEDTACreatinine</td><td rowspan=1 colspan=1>24 mg/dL500 mg/dLLow pool: Serum index = &gt;6 (3+) (Humanlipemia)Mid/High Pool: Serum index = 10(4+)(Human Lipemia)6.0 mg/dL500 mg/dL40 mg/dL16 mg/dL40 mg/dL</td><td rowspan=1 colspan=1>24 mg/dL400 mg/dL400 mg/dL (4+) (Intralipid)3.0 mg/dL500 mg/dL20 mg/dL8 mg/dL30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Anticoagulant</td><td rowspan=1 colspan=1>Lithium Heparin, Sodium Heparin,Potassium Oxalate/Sodium Fluoride</td><td rowspan=1 colspan=1>Ammonium Heparin, Lithium Heparin,Sodium Heparin, PotassiumOxalate/Sodium Fluoride</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>≤5 mg/dL</td><td rowspan=1 colspan=1>&lt;5mg/dL</td></tr></table>

# 8.0 Summary of Non-clinical Performance Data:

A series of studies were performed to evaluate the following non-clinical performance characteristics for the GLUH Reagent: method comparison, anticoagulant, precision, sensitivity, linearity, interferences, sample stability, sample dilution, reagent stability, reference range, and calibration stability experiments.

# Method Comparison

Methods comparison experiments were designed using CLSI Procedure EP9-A2: "Method Comparison and Bias Estimation Using Patients Samples". The patient correlation studies were conducted using the SYNCHRON Glucose (GLU) (Method X) and the candidate UniCel DxC SYNCHRON Systems Glucose (GLUH) (Method Y) for serum and CSF matrices. Patient correlation studies were conducted using the SYNCHRON modular Glucose (GLUCm) (Method X) and the candidate Beckman Coulter UniCel DxC SYNCHRON Systems Glucose (GLUH) (Method Y) for urine samples. A minimum of 100 samples were tested for each matrix.

<table><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Slope</td><td colspan="1" rowspan="1">Intercept</td><td colspan="1" rowspan="1">R</td><td colspan="1" rowspan="1">N</td></tr><tr><td colspan="1" rowspan="1">UniCel DxC600</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0.982</td><td colspan="1" rowspan="1">-1.02</td><td colspan="1" rowspan="1">1.000</td><td colspan="1" rowspan="1">120</td></tr><tr><td colspan="1" rowspan="1">UniCel DxC800</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0.999</td><td colspan="1" rowspan="1">-1.60</td><td colspan="1" rowspan="1">1.000</td><td colspan="1" rowspan="1">120</td></tr><tr><td colspan="1" rowspan="1">UniCel DxC600</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">0.978</td><td colspan="1" rowspan="1">1.25</td><td colspan="1" rowspan="1">1.000</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">UniCel DxC800</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">1.002</td><td colspan="1" rowspan="1">-0.61</td><td colspan="1" rowspan="1">1.000</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">UniCel DxC600</td><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">0.989</td><td colspan="1" rowspan="1">2.08</td><td colspan="1" rowspan="1">1.000</td><td colspan="1" rowspan="1">117</td></tr><tr><td colspan="1" rowspan="1">UniCel DxC800</td><td colspan="1" rowspan="1">Urine-</td><td colspan="1" rowspan="1">0.973b</td><td colspan="1" rowspan="1">2.86</td><td colspan="1" rowspan="1">1.000</td><td colspan="1" rowspan="1">117</td></tr></table>

# Anticoaqulant Studies

Anticoagulant experiments were designed using CLSI Procedure EP14-A2: "Evaluation of Matrix Effects; Approved Guidelines - Second Edition". For each anticoagulant tested, paired plasma and serum samples from healthy volunteers were drawn. Over 50 patient specimens with glucose concentrations spanning the analytical range were obtained and tested internally.

<table><tr><td rowspan=1 colspan=1>DxC600</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Anticoagulant</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Deming RegressionAnalysis</td></tr><tr><td rowspan=1 colspan=1>Sodium Heparin</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>y= 0.983 + 0.849, R= 0.999</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>$y$0.994 +0.393,R= 0.999</td></tr><tr><td rowspan=1 colspan=1>Sodium Fluoride/Potassium Oxalate</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>y= 0.995 + 1.007, R= 0.999.</td></tr><tr><td rowspan=1 colspan=1>DxC800</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Anticoagulant</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Deming RegressionAnalysis             •</td></tr><tr><td rowspan=1 colspan=1>Sodium Heparin</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>y= 0.998 - 0.172, R= 0.999</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>y= 1.02 - 2.476, R= 1.000</td></tr><tr><td rowspan=1 colspan=1>Sodium Fluoride/Potassium Oxalate</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>y= 1.012 - 0.302, R= 0.999</td></tr></table>

# Precision

Precision studies were conducted in accordance with CLSI EP5-A2. Multiple levels of samples were tested 4 times a day for 20 days. The user of a UniCel DxC 600/800 SYNCHRON System(s) should expect the instrument to produce imprecision values less than or equal to the claimed maximum performance limits (S.D. or $\%$ CV). The claimed within run SD is 2.0 mg/dL, and.the claimed total SD is $3 . 0 m g / d L$ . The claimed within run $\% 0 \%$ is 2.0, and the claimed total $\% 0 \%$ is 3.0. The changeover value is $1 0 0 . 0 \ : \mathsf { m g / d L }$ .

<table><tr><td colspan="1" rowspan="1">Type of Imprecision</td><td colspan="1" rowspan="1">SAMPLE TYPE</td><td colspan="1" rowspan="1">SAMPLE</td><td colspan="1" rowspan="1">No. Systems</td><td colspan="1" rowspan="1">No. Data Points</td><td colspan="1" rowspan="1">GLUHGRANDMEAN(mg/dL)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="10">Within Run DxC 600</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Control 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">1.6</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Control 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">219</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">1.0</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Control 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">390</td><td colspan="1" rowspan="1">5.7</td><td colspan="1" rowspan="1">1.5</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Pool 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">3.6</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Pool 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">1.1</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Pool3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">660</td><td colspan="1" rowspan="1">6.4</td><td colspan="1" rowspan="1">1.0</td></tr><tr><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Pool 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">3.2</td></tr><tr><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Pool 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">1.0</td></tr><tr><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Pool 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">670</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">0.8</td></tr><tr><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">Pool 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">3.0</td></tr><tr><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">Pool 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">109</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">Pool3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">677</td><td colspan="1" rowspan="1">7.0</td><td colspan="1" rowspan="1">1.0</td></tr><tr><td colspan="1" rowspan="12">Total DxC 600</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Control 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Control 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">219</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Control 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">390</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">1.7</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Pool 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">5.9</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Pool 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">1.6</td></tr><tr><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Pool3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">660</td><td colspan="1" rowspan="1">8.4</td><td colspan="1" rowspan="1">1.3</td></tr><tr><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Pool 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">5.7</td></tr><tr><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Pool 2</td><td colspan="1" rowspan="1">-1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">1.5</td></tr><tr><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Pool 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">670</td><td colspan="1" rowspan="1">6.1</td><td colspan="1" rowspan="1">0.9</td></tr><tr><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">Pool 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">5.3</td></tr><tr><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">Pool 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">109</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">1.5</td></tr><tr><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">Pool3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">677</td><td colspan="1" rowspan="1">8.6</td><td colspan="1" rowspan="1">1.3</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Type of Imprecision</td><td rowspan=1 colspan=1>SAMPLE TYPE</td><td rowspan=1 colspan=1>SAMPLE</td><td rowspan=1 colspan=1>No. Systems</td><td rowspan=1 colspan=1>No. Data Points</td><td rowspan=1 colspan=1>GLUH GRANDMEAN (mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=12 colspan=1>Within Run DxC 800</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>389</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Pool 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Pool 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Pool3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>662</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Pool 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Pool 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Pool 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>668</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Pool 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Pool 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Pool3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>680</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=12 colspan=1>Total DxC 800</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>389</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Pool 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Pool 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Pool3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>662</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Pool 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Pool 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Pool 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>668</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Pool 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Pool 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Pool3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>680</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>1.2</td></tr></table>

Limit of blank (LoB), limit of detection (LoD), and Limit of Quantitation (LoQ) data analyses were performed in accordance with the CLSI EP17-A2 guideline. Multiple urine, CSF and serum pools were run over multiple days to establish and verify the analytical sensitivity claims. The claimed LoB, LoD and LoQ values are ≤5mg/dL.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Urine</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>0.19 mg/dL</td><td rowspan=1 colspan=1>0.17 mg/dl</td><td rowspan=1 colspan=1>0.19 mg/dL</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.011 mmol/L</td><td rowspan=1 colspan=1>0.009 mmol/L</td><td rowspan=1 colspan=1>0.011 mmol/L</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>1.74 mg/dL</td><td rowspan=1 colspan=1>1.68 mg/dL</td><td rowspan=1 colspan=1>1.78 mg/dL</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.097 mmol/L</td><td rowspan=1 colspan=1>0.093 mmol/L</td><td rowspan=1 colspan=1>0.099 mmol/L</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>3.78 mg/dL</td><td rowspan=1 colspan=1>3.67 mg/dL</td><td rowspan=1 colspan=1>3.69 mg/dL</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.210 mmol/L</td><td rowspan=1 colspan=1>0.204 mmol/L</td><td rowspan=1 colspan=1>0.205 mmol/L</td></tr></table>

# Linearity

The study followed CLSI EP-6A. The testing involves running multiple replicates of the pools over the range of the assay. The concentration Recovery error and %Recovery error were calculated for each sample tested. The recovered concentrations verses the Target concentrations are curve fit with first, second, and third order polynomials. The residual differences for each level between the first order (linear) and the better fitting higher order (second or third polynomial) known as the Nonlinearity Differences are calculated. The data substantiates GLUH test is linear between 5 and $7 0 0 m g / d L$ .

The following are the final linear equations obtained for each matrix:

DxC 600 Serum: $y = 1 . 0 1 0 1 6 x + 1 . 0 8 8 1$ CSF: $y = 1 . 0 0 7 5 x + 1 . 5 1 5 7$ Urine: $y = 1 . 0 0 1 1 x + 0 . 4 4 6 4$

DxC 800 Serum: $y = 1 . 0 0 3 5 x + 2 . 1 9 7 7$ CSF: $y = 1 . 0 0 8 1 x + 1 . 5 7 7 8$ Urine: $y = 0 . 9 9 9 1 x + 1 . 0 6 8$

# Interferences

Interference studies were designed from CLSI Guideline EP7-A: "Interference Testing in Clinical Chemistry - Approved Guideline" and used to assess common or known substances which could interfere with the UniCel $0 \times 0$ SYNCHRON Systems GLUH assay. The experiment involves adding potential interfering substances to patient serum pools to determine the magnitude of the effect. A properly operating UniCel DxC 600/800 SYNCHRON System(s) should exhibit interference values less than or equal to: $\pm 6$ mg/dL or $10 \%$ , with a crossover value of $6 0 m g / d L$ .

<table><tr><td colspan="6" rowspan="1">Low Level Glucose Pool</td></tr><tr><td colspan="1" rowspan="1">Substance</td><td colspan="1" rowspan="1">Source</td><td colspan="1" rowspan="1">MaximumLevelTested</td><td colspan="1" rowspan="1">Target(mg/dL)</td><td colspan="1" rowspan="1">Recovered(mg/dL)</td><td colspan="1" rowspan="1">%recovery*</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">RBChemolysate</td><td colspan="1" rowspan="1">500mg/dL</td><td colspan="1" rowspan="1">45.3</td><td colspan="1" rowspan="1">43.7</td><td colspan="1" rowspan="1">96.5</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">Bovine</td><td colspan="1" rowspan="1">24 mg/dL</td><td colspan="1" rowspan="1">43.4</td><td colspan="1" rowspan="1">42.5</td><td colspan="1" rowspan="1">97.9</td></tr><tr><td colspan="1" rowspan="1">Lipemia</td><td colspan="1" rowspan="1">Human</td><td colspan="1" rowspan="1">(3+)</td><td colspan="1" rowspan="1">46.4</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">97</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">SerumIndex=6</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">AscorbicAcid</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">6.0mg/dL</td><td colspan="1" rowspan="1">43.7</td><td colspan="1" rowspan="1">43.8</td><td colspan="1" rowspan="1">100.2</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">500mg/dL</td><td colspan="1" rowspan="1">54.7</td><td colspan="1" rowspan="1">55.2</td><td colspan="1" rowspan="1">100.9</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">40 mg/dL</td><td colspan="1" rowspan="1">42.9</td><td colspan="1" rowspan="1">44.4</td><td colspan="1" rowspan="1">103.5</td></tr><tr><td colspan="1" rowspan="1">EDTA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">16 mg/dL</td><td colspan="1" rowspan="1">43.6</td><td colspan="1" rowspan="1">43.4</td><td colspan="1" rowspan="1">99.5</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">40 mg/dL</td><td colspan="1" rowspan="1">45.2</td><td colspan="1" rowspan="1">44.4</td><td colspan="1" rowspan="1">98.2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Mi</td><td colspan="1" rowspan="1">Mid Level Glucose Pool</td><td colspan="1" rowspan="1">cose Poo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Substance</td><td colspan="1" rowspan="1">Source</td><td colspan="1" rowspan="1">MaximumLevelTested</td><td colspan="1" rowspan="1">Target(mg/dL)</td><td colspan="1" rowspan="1">Recovered(mg/dL)</td><td colspan="1" rowspan="1">%recovery*</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">RBChemolysate</td><td colspan="1" rowspan="1">500mg/dL</td><td colspan="1" rowspan="1">171.5</td><td colspan="1" rowspan="1">169.1</td><td colspan="1" rowspan="1">98.6</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">Bovine</td><td colspan="1" rowspan="1">24 mg/dL</td><td colspan="1" rowspan="1">168.7</td><td colspan="1" rowspan="1">167.9</td><td colspan="1" rowspan="1">99.5</td></tr><tr><td colspan="1" rowspan="1">Lipemia</td><td colspan="1" rowspan="1">Human</td><td colspan="1" rowspan="1">(4+)SerumIndex =&gt;10</td><td colspan="1" rowspan="1">189.1</td><td colspan="1" rowspan="1">184.6</td><td colspan="1" rowspan="1">97.6</td></tr><tr><td colspan="1" rowspan="1">AscorbicAcid</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">6.0mg/dL</td><td colspan="1" rowspan="1">167.7</td><td colspan="1" rowspan="1">166.4</td><td colspan="1" rowspan="1">99.2</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">500mg/dL</td><td colspan="1" rowspan="1">207.1</td><td colspan="1" rowspan="1">208.9</td><td colspan="1" rowspan="1">100.9</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">40 mg/dL</td><td colspan="1" rowspan="1">166.8</td><td colspan="1" rowspan="1">168.4</td><td colspan="1" rowspan="1">101</td></tr><tr><td colspan="1" rowspan="1">EDTA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">16 mg/dL</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">168.1</td><td colspan="1" rowspan="1">100.7</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">40 mg/dL</td><td colspan="1" rowspan="1">173.8</td><td colspan="1" rowspan="1">173.4</td><td colspan="1" rowspan="1">99.8</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Hig</td><td colspan="1" rowspan="1">h Level Gll</td><td colspan="1" rowspan="1">cose Poo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Substance</td><td colspan="1" rowspan="1">Source</td><td colspan="1" rowspan="1">MaximumLevelTested</td><td colspan="1" rowspan="1">Target(mg/dL)</td><td colspan="1" rowspan="1">Recovered(mg/dL)</td><td colspan="1" rowspan="1">%recovery*</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">RBChemolysate</td><td colspan="1" rowspan="1">500mg/dL</td><td colspan="1" rowspan="1">410.7</td><td colspan="1" rowspan="1">406.1</td><td colspan="1" rowspan="1">98.9</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">Bovine</td><td colspan="1" rowspan="1">24 mg/dL</td><td colspan="1" rowspan="1">407.2</td><td colspan="1" rowspan="1">404.8</td><td colspan="1" rowspan="1">99.4</td></tr><tr><td colspan="1" rowspan="1">Lipemia</td><td colspan="1" rowspan="1">Human</td><td colspan="1" rowspan="1">(4+)SerumIndex =&gt;10</td><td colspan="1" rowspan="1">461.7</td><td colspan="1" rowspan="1">453.1</td><td colspan="1" rowspan="1">98.1</td></tr><tr><td colspan="1" rowspan="1">AscorbicAcid</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">6.0mg/dL</td><td colspan="1" rowspan="1">396.2</td><td colspan="1" rowspan="1">394.6</td><td colspan="1" rowspan="1">99.6</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">500mg/dL</td><td colspan="1" rowspan="1">476</td><td colspan="1" rowspan="1">477.4</td><td colspan="1" rowspan="1">100.3</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">40 mg/dL</td><td colspan="1" rowspan="1">397.1</td><td colspan="1" rowspan="1">405</td><td colspan="1" rowspan="1">102</td></tr><tr><td colspan="1" rowspan="1">EDTA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">16 mg/dL</td><td colspan="1" rowspan="1">402.6</td><td colspan="1" rowspan="1">404.4</td><td colspan="1" rowspan="1">100.4</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">40 mg/dL</td><td colspan="1" rowspan="1">409.4</td><td colspan="1" rowspan="1">411.5</td><td colspan="1" rowspan="1">100.5</td></tr></table>

Listings of drugs, diseases and other pre-analytical variables known to affect glucose measurements when analyzing Serum, Urine and CSF are described in References (1,2,3). Visually turbid urine specimens should be centrifuged prior to analysis.

# References:

Young DEffectsfDrugsonClinical Laboratory Tests th Edition, AACC Pres, Washington, D. C. (2000).   
rB.ou fecs Clncl abatoy Te , AACC Press, Washington, D.C. (2001).

Young. D.S. Effects of Preanalytical Variables on Clinical Laboratory Tests, 3rd Edition, AACC Press, Washington, D. C. (2007).

# Sample dilution

The objective of this testing is to determine and verify the appropriate sample diluent to use when diluting out of range samples using the UniCel DxC SYNCHRON Systems Glucose (GLUH) reagent. Saline was chosen as the appropriate diluent. There was no issue or effect observed when verifying saline as an appropriate sample diluent.

# Reagent stability

The UniCel DxC SYNCHRON Systems Glucose (GLUH) Reagent was tested to verify the onboard stability claim on the UniCel DxC 600/800 SYNCHRON System(s) family of Clinical Chemistry analyzers. The performance assessment involves assaying multiple levels of pooled sera at regular intervals throughout the testing period. The assay was calibrated at 14 day intervals. To be considered acceptable, recovered values must fall within the expected ranges. The testing establishes that the GLUH reagent is stable on board for 30 days.

# Reference range

Samples reference intervals are based on published literature references.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Literature reference</td></tr><tr><td rowspan=1 colspan=1>Serum/Plasma</td><td rowspan=1 colspan=1>74-106 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>1-15 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Urine (timed)</td><td rowspan=1 colspan=1>&lt;0.5g/24 hours</td></tr><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>40-70 mg/dL</td></tr></table>

Literature References   
Tietz, N. W., ed., Fundamentals of ·Clinical Chemistry, 6th Edition, W. B. Saunders; Philadelphia, PA (2007).   
Pagana, K D and Pagana, T J, Mosby's Manual of Diagnostic and Laboratory Tests 3rd Edition , Mosby Inc., St Louis, MO (2006).

# 9.0 Conclusion:

The data for the UniCel DxC SYNCHRON Systems Glucose Reagent (GLUH), in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to the currently cleared SYNCHRON Systems Glucose Reagent (GLU, K883181). Equivalence is demonstrated through method comparison, anticoagulant, precision, sensitivity, linearity, interferences, sample stability, sample dilution, reagent stability, reference range, and calibration stability experiments.

BECKMAN COULTER, INC. YVETTE LLOYD   
250 S. KRAEMER ST   
BREA CA 92821

Re: K131189 Trade/Device Name: UniCel DxC SYNCHRON Systems Glucose Reagent (GLUH) Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: II Product Code: CFR Dated: April 11, 2014 Received: April 14, 2014

Dear Ms. Lloyd:

We have reviewed your Section $\$ 10( k)$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2—Ms. Lloyd

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809). please contact the Division of Small Manufacturers. International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also. please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adversc events under the MDR regulation (21 CFR Part 803). please go to   
http://www.fda.gov/MedicalDevices/Safety/ReporaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consuiner Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http:/www.fda.gov/McdicalDevices/RcsourcesforYou/Industry/default.htm.

Sincerely yours,

# Courtney H. Lias -S

Courtncy H. Lias. Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

510(k) Number (if known) K131189

Device Name UniCel DxC SYNCHRON Systems Glucose Reagent (GLUH)

Indications for Use (Describe)   
UniCel Dx SYNCHRON Systems Glucose Reagent (GLUH), when used in conjunctn with UniCel DxC 600/800 SYNCHRON SmNCH QU human serum, plasma, urine or cerebrospinal fluid (CSF).

neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.

# This section applies only to requlrements of the Paperwork Reduction Act of 1995.

# DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

Theburden imeorhis collection  inomation is estated toveragehours per esonse,nclud tme to reviw instructions, search existing dat sources, gather and maintain he data needed and coplee and review the collection of information. Send comments regarding this burden estimate or any other aspect oation collectionncdn ggestions o educighi ur

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."